-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 K3Kkcc2aAJS0z3IXleGGnnMF23ZqLvVQrpMKjzF6F9Pv+dBurGX2k9uo9pfcLCaA
 LQCZXRQpVioZlMsCapQmKg==

<SEC-DOCUMENT>0001130319-06-000456.txt : 20060605
<SEC-HEADER>0001130319-06-000456.hdr.sgml : 20060605
<ACCEPTANCE-DATETIME>20060605121628
ACCESSION NUMBER:		0001130319-06-000456
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20060605
FILED AS OF DATE:		20060605
DATE AS OF CHANGE:		20060605

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOLYTICS BIOTECH INC
		CENTRAL INDEX KEY:			0001129928
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-31062
		FILM NUMBER:		06885337

	BUSINESS ADDRESS:	
		STREET 1:		1167 KENSINGTON CRES NW SUITE 210
		STREET 2:		CALGARY ALBERTA CANADA T2N 1X7
		CITY:			ALBERTA CANADA
		STATE:			A0
		ZIP:			00000
		BUSINESS PHONE:		4036707380

	MAIL ADDRESS:	
		STREET 1:		210 - 1167 KENSINGTON CRES NW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2N 1X7
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>o31890e6vk.htm
<DESCRIPTION>FORM 6-K: PRESS RELEASE DATED JUNE 5TH, 2006
<TEXT>
<HTML>
<HEAD>
<TITLE>Form 6-K: Press Release Dated June 5th, 2006</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<HR size="4" noshade color="#000000" style="margin-top: -5px">
<HR size="1" noshade color="#000000" style="margin-top: -10px">

<P align="center" style="font-size: 14pt"><B>SECURITIES AND EXCHANGE COMMISSION<BR>
<DIV align="center" style="font-size: 12pt">Washington, D.C.
20549</DIV></B>


<P align="center" style="font-size: 18pt"><B>Form 6-K</B>

<P align="center" style="font-size: 10pt"><B>Report of Foreign Private Issuer</B>

<P align="center" style="font-size: 10pt"><B>Pursuant to Rule&nbsp;13a-16 or 15d-16<BR>
of the Securities Exchange Act of 1934</B>

<P align="center" style="font-size: 10pt">For the month of June 2006

<P align="center" style="font-size: 10pt">Commission File Number 000-31062

<CENTER>
<P align="center" style="font-size: 24pt"><B>Oncolytics Biotech Inc.</B>
<HR size="1" width="45%" noshade>
<DIV align="center" style="font-size: 10pt"><I>(Translation of registrant&#146;s name into
English)</I>
</DIV>
</CENTER>

<CENTER>
<P align="center" style="font-size: 10pt"><B>Suite&nbsp;210, 1167 Kensington Crescent NW<BR>
Calgary, Alberta, Canada T2N 1X7</B>
<HR size="1" width="45%" noshade>
<DIV align="center" style="font-size: 10pt"><I>(Address of principal executive offices)</I>
</DIV>
</CENTER>

<P style="font-size: 10pt">Indicate by check mark whether the registrant files or will file annual reports
under cover Form&nbsp;20-F or Form&nbsp;40-F.

<CENTER>
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="70%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">

<TD align="center" valign="top">Form&nbsp;20-F&nbsp;&nbsp;&nbsp;<FONT
face="wingdings">&#111;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Form&nbsp;40-F&nbsp;&nbsp;&nbsp;<FONT
face="wingdings">&#254;</FONT></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</CENTER>

<P style="font-size: 10pt">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K in paper as
permitted by Regulation&nbsp;S-T Rule&nbsp;101(b)(1):&nbsp;&nbsp;&nbsp;<FONT
face="wingdings">&#111;</FONT>

<P style="font-size: 10pt"><B>Note: </B>Regulation&nbsp;S-T Rule&nbsp;101(b)(1) only permits the submission in paper of a
Form&nbsp;6-K if submitted solely to provide an attached annual report to security
holders.

<P style="font-size: 10pt">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K in paper as
permitted by Regulation&nbsp;S-T Rule&nbsp;101(b)(7):&nbsp;&nbsp;&nbsp;<FONT
face="wingdings">&#111;</FONT>

<P style="font-size: 10pt"><B>Note: </B>Regulation&nbsp;S-T Rule&nbsp;101(b)(7) only permits the submission in paper of a
Form&nbsp;6-K if submitted to furnish a report or other document that the registrant
foreign private issuer must furnish and make public under the laws of the
jurisdiction in which the registrant is incorporated, domiciled or legally
organized (the registrant&#146;s &#147;home country&#148;), or under the rules of the home
country exchange on which the registrant&#146;s securities are traded, as long as
the report or other document is not a press release, is not required to be and
has not been distributed to the registrant&#146;s security holders, and, if
discussing a material event, has already been the subject of a Form&nbsp;6-K
submission or other Commission filing on EDGAR.

<P style="font-size: 10pt">Indicate by check mark whether by furnishing the information contained in this
Form, the registrant is also thereby furnishing the information to the
Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of
1934.

<CENTER>
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="70%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top">Yes&nbsp;&nbsp;&nbsp;<FONT
face="wingdings">&#111;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">No&nbsp;&nbsp;&nbsp;<FONT
face="wingdings">&#254;</FONT></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</CENTER>

<P style="font-size: 10pt">If &#147;Yes&#148; is marked, indicate below the file number assigned to the registrant
in connection with Rule&nbsp;12g3-2(b):&nbsp;&nbsp;&nbsp;82&nbsp;-&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>

<P>
<HR size="1" noshade color="#000000" style="margin-top: -2px">
<HR size="4" noshade color="#000000" style="margin-top: -10px">

<P style="font-size: 10pt">&nbsp;

</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<!-- TOC -->
<A name="toc"><DIV align="CENTER" style="page-break-before:always"><U><B>TABLE OF CONTENTS</B></U></DIV></A>

<P><CENTER>
<TABLE border="0" width="90%" cellpadding="0" cellspacing="0">
<TR>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="76%"></TD>
</TR>
<TR><TD colspan="9"><A HREF="#000">Signatures</A></TD></TR>
</TABLE>
</CENTER>
<!-- /TOC -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<!-- link1 "Signatures" -->
<DIV align="left"><A NAME="000"></A></DIV>

<P align="center" style="font-size: 10pt"><B>SIGNATURES</B>

<P style="font-size: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.

<P>
<CENTER>
<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR valign="bottom">
    <TD width="50%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>

<TD colspan="3" align="left" valign="top"><B>Oncolytics
Biotech Inc.</B><BR>
(Registrant)</TD>
</TR>
<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR><TD>&nbsp;</TD></TR>
<TR valign="bottom">
    <TD valign="top">Date: June 5, 2006</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Doug Ball
<HR size="1" noshade width="60%">
Doug Ball<BR>
Chief Financial Officer</TD>
</TR>
</TABLE>
</CENTER>

<P align="center" style="font-size: 10pt">&nbsp;

</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<P>
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<TR valign="top">
        <TD width="70%"><IMG src="o31890o3189000.gif" alt="Oncolytics Biotech Logo"></TD>
        <TD width="30%">210, 1167 Kensington Crescent NW<BR>
Calgary, Alberta<BR>
Canada T2N 1X7</TD>
</TR>
</TABLE>

<P align="left" style="font-size: 10pt"><B><HR align="left" size="1" width="100%" noshade></B>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>FOR IMMEDIATE RELEASE</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 18pt"><B>Oncolytics Biotech Inc. Completes Patient Enrolment in<BR>
UK Phase I Systemic Administration Clinical Trial</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>CALGARY, AB, &#151; June&nbsp;5, 2006 </B>- Oncolytics Biotech Inc. (&#147;Oncolytics&#148;) (TSX:ONC, NASDAQ:ONCY) is
pleased to announce that it has completed patient enrolment in the dose escalation portion of its
U.K. Phase I systemic administration clinical trial investigating the use of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top"><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP></SUP>
to treat patients with advanced cancers. A total of 30 patients were treated in the trial at
escalating frequency and dosage to a maximum daily dose of 1x10<SUP style="font-size: 85%; vertical-align: text-top">11</SUP> TCID<SUB style="font-size: 85%; vertical-align: text-bottom">50. </SUB>A
maximum tolerated dose (MTD)&nbsp;was not reached and the treatment appears to have been well tolerated
by the patients.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Interim results of the trial, which were presented at the American Society of Clinical Oncology
(ASCO)&nbsp;Annual Meeting on June&nbsp;4, 2006 in Atlanta, Georgia, indicated that REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top"><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP></SUP> can
be delivered systemically to various tumour types and cause virus-mediated tumour responses.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The primary objective of the Phase I trial is to determine the MTD, dose limiting toxicity (DLT),
and safety profile of REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top"><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP></SUP> when administered systemically to patients. A secondary
objective is to examine any evidence of anti-tumour activity. Eligible patients include those who
had been diagnosed with advanced or metastatic solid tumours that are refractory (have not
responded) to standard therapy or for which no curative standard therapy exists. The principal
investigator for the study is Dr.&nbsp;Johann de Bono of The Royal Marsden NHS Foundation Trust and
The Institute of Cancer Research, London.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>About Oncolytics Biotech Inc.</B><BR>
Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses
as potential cancer therapeutics. Oncolytics&#146; clinical program includes a variety of Phase I and
Phase I/II human trials using REOLYSIN<SUP style="font-size: 85%; vertical-align: text-top"><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP></SUP>, its proprietary formulation of the human
reovirus, alone and in combination with radiation. For further information about Oncolytics,
please visit <U>www.oncolyticsbiotech.com</U>
</DIV>

<DIV align="left" style="font-size: 8pt; margin-top: 6pt"><I>This press release contains forward-looking statements, within the meaning of Section&nbsp;21E of
the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the
Company&#146;s expectations related to the results of the Phase I UK Systemic Administration clinical
trial investigating delivery of REOLYSIN</I><SUP style="font-size: 85%; vertical-align: text-top"><I><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP></I></SUP><I> for advanced cancers, and the Company&#146;s belief
as to the potential of REOLYSIN</I><SUP style="font-size: 85%; vertical-align: text-top"><I><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP></I></SUP><I> as a cancer therapeutic, involve known and unknown
risks and uncertainties, which could cause the Company&#146;s actual results to differ materially from
those in the forward-looking statements. Such risks and uncertainties include, among others, the
availability of funds and resources to pursue research and development projects, the efficacy of
REOLYSIN</I><SUP style="font-size: 85%; vertical-align: text-top"><I><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP></I></SUP><I> as a cancer treatment, the success and timely completion of clinical studies
and trials, the Company&#146;s ability to successfully commercialize REOLYSIN</I><SUP style="font-size: 85%; vertical-align: text-top"><I><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP></I></SUP><I>, uncertainties
related to the research and development of pharmaceuticals and uncertainties related to the
regulatory process. Investors should consult the Company&#146;s quarterly and annual filings with the
Canadian and U.S. securities commissions for additional information on risks and
uncertainties relating to the forward looking statements. Investors
are cautioned against placing undue reliance on forward-looking statements. The Company does not
undertake to update these forward-looking statements.</I>
</DIV>



<P align="left" style="font-size: 10pt"><B>FOR FURTHER INFORMATION PLEASE CONTACT:</B>

<CENTER>
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<TR valign="bottom">
    <TD width="32%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="58%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">Oncolytics Biotech Inc.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">The Equicom Group</TD>
</TR>

<TR valign="bottom">
    <TD valign="top">Cathy Ward</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Nick Hurst</TD>
</TR>

<TR valign="bottom">
    <TD valign="top">210, 1167 Kensington Cr NW</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">20 Toronto Street</TD>
</TR>

<TR valign="bottom">
    <TD valign="top">Calgary, Alberta T2N 1X7</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Toronto, Ontario M5C 2B8</TD>
</TR>

<TR valign="bottom">
    <TD valign="top">Tel: 403.670.7377</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tel: 416.815.0700 ext. 226</TD>
</TR>

<TR valign="bottom">
    <TD valign="top">Fax: 403.283.0858</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax: 416.815.0080</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><U>cathy.ward@oncolytics.ca</U></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><U>nhurst@equicomgroup.com</U></TD>
</TR>

<TR valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD align="left" valign="top">The Investor Relations Group</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">RenMark Financial Communications</TD>
</TR>

<TR valign="bottom">
    <TD align="left" valign="top">Damian McIntosh</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">John Boidman</TD>
</TR>

<TR valign="bottom">
    <TD align="left" valign="top">11 Stone Street, 3rd Floor</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2080 Rene Levesque Blvd. W.</TD>
</TR>

<TR valign="bottom">
    <TD align="left" valign="top">New York, NY 10004</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Montreal, PQ H3H&nbsp;1R6</TD>
</TR>

<TR valign="bottom">
    <TD align="left" valign="top">Tel: 212.825.3210</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tel: 514.939.3989</TD>
</TR>

<TR valign="bottom">
    <TD align="left" valign="top">Fax: 212.825.3229</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax: 514.939.3717</TD>
</TR>

<TR valign="bottom">
    <TD align="left" valign="top"><U>dmcintosh@investorrelationsgroup.com</U></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><U>jboidman@renmarkfinancial.com</U></TD>
</TR>
</TABLE>
</CENTER>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">-30-
</DIV>




</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>o31890o3189000.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 o31890o3189000.gif
M1TE&.#EA\@`W`/<``/______S/__F?__9O__,___`/_,___,S/_,F?_,9O_,
M,__,`/^9__^9S/^9F?^99O^9,_^9`/]F__]FS/]FF?]F9O]F,_]F`/\S__\S
MS/\SF?\S9O\S,_\S`/\`__\`S/\`F?\`9O\`,_\``,S__\S_S,S_F<S_9LS_
M,\S_`,S,_\S,S,S,F<S,9LS,,\S,`,R9_\R9S,R9F<R99LR9,\R9`,QF_\QF
MS,QFF<QF9LQF,\QF`,PS_\PSS,PSF<PS9LPS,\PS`,P`_\P`S,P`F<P`9LP`
M,\P``)G__YG_S)G_F9G_9IG_,YG_`)G,_YG,S)G,F9G,9IG,,YG,`)F9_YF9
MS)F9F9F99IF9,YF9`)EF_YEFS)EFF9EF9IEF,YEF`)DS_YDSS)DSF9DS9IDS
M,YDS`)D`_YD`S)D`F9D`9ID`,YD``&;__V;_S&;_F6;_9F;_,V;_`&;,_V;,
MS&;,F6;,9F;,,V;,`&:9_V:9S&:9F6:99F:9,V:9`&9F_V9FS&9FF69F9F9F
M,V9F`&8S_V8SS&8SF68S9F8S,V8S`&8`_V8`S&8`F68`9F8`,V8``#/__S/_
MS#/_F3/_9C/_,S/_`#/,_S/,S#/,F3/,9C/,,S/,`#.9_S.9S#.9F3.99C.9
M,S.9`#-F_S-FS#-FF3-F9C-F,S-F`#,S_S,SS#,SF3,S9C,S,S,S`#,`_S,`
MS#,`F3,`9C,`,S,```#__P#_S`#_F0#_9@#_,P#_``#,_P#,S`#,F0#,9@#,
M,P#,``"9_P"9S`"9F0"99@"9,P"9``!F_P!FS`!FF0!F9@!F,P!F```S_P`S
MS``SF0`S9@`S,P`S````_P``S```F0``9@``,P``````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````"'Y!```````+`````#R`#<```C_``$('$BPH,&#
M"!,J7,BPH<.'$"-*G$BQHL6&*S)FO,BQH\>/($.*I&B%2R!6UZ#-NG8-):M`
M5E:,G$FSILV;%U><O!:-):M9UEK):GEM:,N8.),J7<J4XXJ?UJX)5<FJ5*"K
MK++V1#DTD,RF8,.*9>I2ZDLK"E=88=6*Z,NQ<./*O;C6+5*':HG.8O5UKM^_
M@`4&*AJ-%=J).EE!.QJXL>.F.HEZS8D(Y;7#CS-K%CDX*^:+)#I?WDRZ=$71
MGSNB-LVZM4(K1:_U!0E;5K39KG.;7A'-=FJ0@7JSTDW<-"O;@6RBC,:EN//'
M=5D9L!F#55#<S[/#13D+^\A`0)-K_Q\_%C:TX3A70&M+OCW8K+-^T^PLWKU]
MFT];+ETQ%/W]_R/5M@=9O0%H8$@[R5=3(+X=Z"!'+GE7DX`(77450E5<)6%!
M5IR4U5D;"J26AUG!%"(`.L'$4(<:)L3B9RQ:*..,V*6H($$C?HB(B@DE]F&)
M=QWD$F2S1',(0L<)=U`7*-V(HF4E[E24@FNY]%(@B*C$&$)UU:=09WP=-)@L
M_@F4E5MHEO5;EU]"N6,I9X;)(906PJ>2EP.MT%*92J7$YT"L]+:507IL*29+
MDQ6TD9@1&O145][!EI5#@^V%6V>F,-3H0I+^*:)+7>"V*(<^U:@60OQ=@V=2
M/WD*P'&7;?\JD!4K*>C2JISVIU`I;>%J15</!;*8G*^R=*2F0YT(P*^J'O24
M2D]`Q."D$?$F"ZXW68:D5``P6%A?YG5QT%I[2812*T[6=IM!5O26:;"V\179
M6PT%VMV*[AXZBQ[56AF3LB(6B:U-K5CCJF+7"&:-I;,V>>AYU<ZR6(C\];:F
M;<?"N^=*`QL$E;*_&GD040`;Y.$U*[%RR+\]+EP*6&8A"50`@D5CL$RUR3=F
MQ\ZB;`T+"I5`V)KY1K23=3P7I-B]G!:-8ZD5=7AF3RT=(N&03/%G,)(J]<5%
M6WQ5T9;.\59[WF@]VA8?NQA/M),@$?TDVXIM>XQ2#!ZIM5S"0K;_5/)'[<XR
M8-_0S%8;*RQ8$XU\UA)+Z9ZO]0;-`>P6]:[1+:T2-S2R@&RYOI=W]&@KWNWT
MMT>!%&SK+$P/U&Y+M7*YE9-]H^WHN8",&VC&$.TQ%-P0R0WR[@>5<,AB5N<=
MJ#61HLSO4M:U,AWAV-7%^8WDGF=%3-N79`KC.\'T;XZ&DDIF]^@'>1`7O;T<
M?-<K?EYAH-=NK];V+1+D4O=JC=B?@GJB5E)4@#)H).1,D9(;[:2V$K>88F4N
M.HG$)N@N+FRH+E1CB0;GEA`]%(EW]9+8\)K5HT"8HBPN.42B1(25#4+)%"OL
M6^MN<@7D*$0%"R%!M4;E$!)H9`4X?!"._S2"EXRPK"&_@AA.`J"XS@GQB161
M"O-P4IND0?&*)@N*JT#R%)2<#HM8W)]R$`7&,CJD+AP<"2"$LL4\H4@D/.S1
M&P$FDY+%T5D$T:'H&/)%$?7Q4"B9B14*MCA-&>8D/`L$"&\G/L.DI4/7XM'\
MKK*]A5"R0R%*XPPI\I00P48\:UF(C3K4$5@YKB.#7)@5S\*BA7`A=(Y*(P!L
MEQ!9SJ]["Z%7O<1G!6C0#B-\<Y%A^!+*A!B`EJ)CB]\`=XV@6/%57M%;B/:P
M2!PY4D2R@`)#2,<0#=VQ(!=RR&4TLDG$G))#LE@6*P#1QA)<DXMG0B9B1/-,
M:'8OANSBF4ZZMY*'7[X*9+QTT@JN`(CN!1%)?3FG1)["*?2L0!#Z#.AK%+HM
ME.`3(FM16SW-R%&3$4557^RB%/W9T9(Z2F*R*-@[2\B=/?W1I"8USUY\PLKM
MF80M05G8>5X*TYY&IX!`*5A;;";%5I0";SU-:D5&I)*<`J4W>S&14J?JE!]J
8I`14S:I6M\K5KGKUJV`-JUC'NM6````[
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
